- Home
- HOTH vs MRKR Comparison
HOTH vs MRKR Comparison
Compare HOTH & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOTH
- MRKR
- Stock Information
- Founded
- HOTH 2017
- MRKR N/A
- Country
- HOTH United States
- MRKR United States
- Employees
- HOTH N/A
- MRKR N/A
- Industry
- HOTH Biotechnology: Pharmaceutical Preparations
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- HOTH Health Care
- MRKR Health Care
- Exchange
- HOTH Nasdaq
- MRKR Nasdaq
- Market Cap
- HOTH 15.6M
- MRKR 17.7M
- IPO Year
- HOTH 2019
- MRKR N/A
- Fundamental
- Price
- HOTH $1.31
- MRKR $1.35
- Analyst Decision
- HOTH Strong Buy
- MRKR Strong Buy
- Analyst Count
- HOTH 3
- MRKR 3
- Target Price
- HOTH $4.00
- MRKR $13.17
- AVG Volume (30 Days)
- HOTH 426.2K
- MRKR 3.5M
- Earning Date
- HOTH 05-12-2025
- MRKR 08-13-2025
- Dividend Yield
- HOTH N/A
- MRKR N/A
- EPS Growth
- HOTH N/A
- MRKR N/A
- EPS
- HOTH N/A
- MRKR N/A
- Revenue
- HOTH N/A
- MRKR $5,696,123.00
- Revenue This Year
- HOTH N/A
- MRKR N/A
- Revenue Next Year
- HOTH N/A
- MRKR $7.16
- P/E Ratio
- HOTH N/A
- MRKR N/A
- Revenue Growth
- HOTH N/A
- MRKR 71.53
- 52 Week Low
- HOTH $0.58
- MRKR $0.95
- 52 Week High
- HOTH $3.80
- MRKR $5.95
- Technical
- Relative Strength Index (RSI)
- HOTH 51.27
- MRKR 40.86
- Support Level
- HOTH $1.21
- MRKR $1.41
- Resistance Level
- HOTH $1.41
- MRKR $1.61
- Average True Range (ATR)
- HOTH 0.10
- MRKR 0.31
- MACD
- HOTH -0.01
- MRKR -0.04
- Stochastic Oscillator
- HOTH 41.30
- MRKR 2.15
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.